Business
Exclusive | Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
said it has reached a deal to acquire Xoma XOMA 0.03%increase; green up pointing triangle Royalty, a company that invests in a range of biotech firms, for around $740 million.
The details
Under the terms, Ligand will pay $39 a share in cash for Xoma, a 2.9% premium over the $37.90 closing price on Friday. The deal is expected to close in the third quarter.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
You must be logged in to post a comment Login